October 9, 2018

San Francisco, California

Patient Centric Drug Development in the Digital Era

 

Translational Science Forum

 

Program

Subject to Change

8:00 AM

ARRIVAL

Registration and Breakfast

8:45 AM

WELCOMING REMARKS

Raffaella Faggioni, Senior Director, MedImmune

9:00 AM

OPENING KEYNOTE SPEECH

Jeff Bluestone, Distinguished Professor of Metabolism and Endocrinology, UCSF and
President and CEO, Parker Institute for Cancer Immunotherapy

9:30 AM

KEYNOTE SPEECH
Philip Nelson, Director of Engineering, Google Research

10:00 AM

BREAK

10:30 AM

Session 1: Digital Transformation in Drug Development Process

Presentations, Followed by Q&A

Introduction by David Fenstermacher, Vice President of Bioinformatics, MedImmune

Data Platform to Measure Health and Disease
Christine Lemke, Co-​Founder and President, Evidation

Achieving Patient-​Centered Disease Management Through Innovative Devices

Sathya Elumalai, CEO, Multisensor Diagnostics

11:30 AM

NETWORKING LUNCH

1:00 PM

KEYNOTE SPEECH
Digital Health -​ Disruptive Technology or Just a Disruption?
Lisa Suennen, Managing Partner, Venture Valkyrie, LLC

1:30 PM

Case Study in Digital Health Business Model
Jeff Elton, Chief Executive Officer, Concerto HealthAI

2:00 PM

The Promise of Digital Technology in Drug Development Clinical Trials
Ann Taylor, Vice President of Clinical Development, MedImmune

2:30 PM

BREAK

2:45 PM

Session 2: Patient-​Centric Drug Development

Presentations, Followed by Q&A

Introduction by Anand Subramony, Vice President of R&D, MedImmune

Engaging Patients in Clinical Trials

Bray Patrick Lake, Director of Patient Engagement, Duke Clinical Research Institute

Accelerating Biomedical Research by Putting Patients First
Noah Craft, Co-​Founder and CEO, Science 37

Transforming Clinical Research with Real-​World Data: Current Practices and Evolving Applications
Jennifer Stacey, Vice President of Clinical Sciences, TriNetX

Eliminating On-​Site Visits Using Digital Clinical Trial Approaches

John Reites, Chief Product Officer, THREAD

4:30 PM

FIRESIDE CHAT: Machine Learning as a New Tool for Drug Discovery

Daphne Koller, Founder and CEO, insitro

Moderator: David Fenstermacher, Vice President of Bioinformatics, MedImmune

5:00 PM

WRAP UP PLENARY SPEECH
Matt Bell, Chief Operating Officer, MedImmune

5:15 PM

NETWORKING RECEPTION    

 

© MedImmune 2018